Jakarta (ANTARA) - State-owned pharmaceutical company PT Bio Farma utilizes the momentum of the G20 Summit to bolster international collaboration in a bid to improve production capacity to meet global demand for vaccines and drugs.

"As we recover from the pandemic, there is a G20 event, and we use it for collaboration. We maintain international cooperation established during the pandemic. We even intensify it," Director of Transformation and Digital of PT Bio Farma Soleh Ayubi stated here on Tuesday.

Three stages experienced by the company -- the pre-pandemic phase, pandemic phase, and the post-pandemic phase -- have significantly affected its performance, Ayubi said.

Ayubi explained that during the pre-pandemic phase, Bio Farma was one of the world's top five vaccine manufacturers. Bio Farma routinely exported polio vaccines to 150 countries and controls 70 percent of the global market share.

However, when it entered the pandemic phase, Bio Farma faced new challenges, such as the shortage of raw materials, as 95 percent of them were imported, and the disconnection of health services throughout Indonesia. However, those challenges were also experienced by large companies around the world.

During this pandemic phase, various researchers and pharmaceutical companies around the world collaborated to create the COVID-19 vaccine and various treatments.

Meanwhile, during the post-pandemic phase, the existing cooperation that intensified during the pandemic should be continued to prepare a better health system and to anticipate the potential for the next pandemic, Ayubi added.

Bio Farma has established several international collaborations at the G20 State-owned-Enterprise (SoE) International Conference & Expo 2022.

The collaborations include between Bio Farma and Suzhou Ronnsi Pharma Co Ltd regarding raw materials and with ConnectedLife Health Singapore in the commercialization of preventive care services.

Bio Farma is also ready to produce 20 million doses of the IndoVac COVID-19 vaccine by the end of this year and is able to produce 120 million doses that can also be used for export.

Related news: BPOM issues EUA for IndoVac booster
Related news: Ministry seeks to plug COVID vaccine shortage with domestic vaccines
Related news: Bio Farma projects IndoVac manufacturing 100 million doses in 2023

Translator: Adhitya Ramadhan, Fardah
Editor: Sri Haryati
Copyright © ANTARA 2022